Figure 8

HOXD8 expression levels in human serum. Fifty-two patients were divided in four groups. The patients with recurrent and cisplatin-resistant ovarian cancer had higher expression levels of HOXD8 than patients with primary malignant tumours (p = 0.02, p = 0.001) or benign tumours (p = 0.001, P < 0.001). However, the difference between the primary malignant ovarian tumour group and benign ovarian tumour group was not statistically significant (P = 0.1).